PF-06863135 (PF-3135 or elranatamab), a humanized IgG2a anti-BCMA/CD3 bispecific MoAb, has a dose-dependent action [100] and is currently evaluated in the ongoing phase I MagnetisMM-1 trial (NCT03269136) in patients with pluri-relapsed MM. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.